- Home
- KMI vs XOMAP Comparison
KMI vs XOMAP Comparison
Compare KMI & XOMAP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | KMI | XOMAP |
|---|---|---|
| Founded | 1936 | N/A |
| Country | United States | United States |
| Employees | N/A | 13 |
| Industry | Natural Gas Distribution | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 58.3B | N/A |
| IPO Year | 2011 | N/A |
Fundamental Metrics
Financial Performance| Metric | KMI | XOMAP |
|---|---|---|
| Price | $27.79 | $26.50 |
| Analyst Decision | Buy | |
| Analyst Count | 13 | 0 |
| Target Price | ★ $31.62 | N/A |
| AVG Volume (30 Days) | ★ 13.6M | N/A |
| Earning Date | 01-21-2026 | N/A |
| Dividend Yield | ★ 4.21% | N/A |
| EPS Growth | ★ 7.28 | N/A |
| EPS | ★ 1.22 | N/A |
| Revenue | ★ $16,416,000,000.00 | N/A |
| Revenue This Year | $12.25 | N/A |
| Revenue Next Year | $4.65 | N/A |
| P/E Ratio | $22.76 | ★ N/A |
| Revenue Growth | ★ 8.35 | N/A |
| 52 Week Low | $23.94 | N/A |
| 52 Week High | $31.48 | N/A |
Technical Indicators
Market Signals| Indicator | KMI | XOMAP |
|---|---|---|
| Relative Strength Index (RSI) | 60.08 | 51.43 |
| Support Level | $26.78 | $26.38 |
| Resistance Level | $27.44 | $26.62 |
| Average True Range (ATR) | 0.49 | 0.14 |
| MACD | 0.11 | 0.01 |
| Stochastic Oscillator | 85.46 | 47.44 |
Price Performance
Historical ComparisonAbout KMI Kinder Morgan Inc.
Kinder Morgan operates natural gas, crude oil, and refined products pipelines connecting producing regions to demand centers. It is principally involved in the gathering, storage, and transmission of natural gas across the continental United States. It also operates distribution centers for refined products along with the largest fleet of Jones Act-compliant tankers.
About XOMAP XOMA Corporation 8.625% Series A Cumulative Perpetual Preferred Stock
XOMA Royalty Corp is a biotechnology royalty aggregator playing a role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceuticals or biotechnology companies. XOMA acquires future economic rights, the seller receives non-dilutive, non-recourse funding that can use to advance their internal drug candidate(s) or for general corporate purposes. Geographically, the company operates in Switzerland, United States, Asia Pacific, Europe and Others.